Reviews/Parkinsons Disease Management/Pimavanserin improves Parkinson's psychosis without worsening motor symptoms
PD NM · PD-06 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Pimavanserin is a drug for the hallucinations and delusions that affect many people with Parkinson's disease. One well-run six-week trial [1] found it reduced psychosis symptoms more than a dummy pill, and the researchers reported no worsening of movement. A second, smaller trial [2] pointed the same way but only reached significance on some psychosis measures, not its main one. Several longer, uncontrolled studies that followed patients over time [3][4][5][6][7] show the benefit holding up and the drug being reasonably tolerated. The main limits are that the clear efficacy result leans on a single pivotal trial, and the 'no motor harm' part comes from short studies where movement was only a secondary check. For those reasons the panel treated the claim as well supported but not fully settled.
The pivotal six-week RCT [1] reported a SAPS-PD change of -5.79 with pimavanserin versus -2.73 with placebo (difference -3.06, 95% CI -4.91 to -1.20; p=0.001; Cohen's d 0.50) and 'no significant safety concerns or worsening of motor function.' The second RCT [2] 'did not impair motor function' but on efficacy its SAPS total 'only showed a trend,' reaching significance only on selected psychosis measures. Open-label and pooled analyses [3][4][5][6] show durable psychosis improvement, including a 76% documented improvement in a chart review [3] and preserved effect across cognitive strata [5]. Long-term open-label safety data [7] over roughly 11 years reported a 'favorable benefit/risk profile' with 'no unexpected safety concerns.' The contested point: The division is over how much weight the efficacy limb can bear: the Synthesist reads a consistent, uniformly positive body, while the Sceptic notes that this rests on one positive pivotal RCT [1] with the only other RCT [2] positive only on secondary measures. The motor-non-worsening limb is similarly tested only in short, efficacy-powered trials with motor as a secondary endpoint.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Parkinsons Disease Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The psychosis-efficacy limb rests chiefly on a single positive pivotal RCT [1]; the only other RCT [2] met just secondary measures, its SAPS total showing 'only... a trend'. One positive confirmatory trial is thin for an 'improves' claim.
The supportive bulk [3][4][5][6][9] is open-label/single-arm/retrospective with no concurrent comparator; OLE placebo arms improved during open-label pimavanserin [4][6], consistent with regression-to-baseline rather than drug effect.
Where it remains uncertain. The efficacy limb rests chiefly on one pivotal RCT [1], the other RCT [2] met only secondary psychosis endpoints, and motor non-worsening is drawn from short trials [1][2] where motor was a secondary measure.
Aleatory
SAPS-PD change carries substantial spread even within pimavanserin-treated patients [6] (change -1.8 with SD 5.5), so individual benefit varies.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT evidence for the psychosis-improvement limb.
“Overall, pimavanserin was well tolerated with no significant safety concerns or worsening of motor function.”
Panel auditInternal validity: high · scope of inference: Adults aged 40+ with Parkinson's disease psychosis not on antipsychotics, over 6 weeks.Key limitations: 6-week duration only · motor non-worsening asserted without numbers in abstract · more discontinuations for adverse events on pimavanserin
Second RCT corroborating both limbs at a motor-sparing dose.
“The principal measures of efficacy of antipsychotic response to pimavanserin, the SAPS total domain score, only showed a trend.”
Panel auditInternal validity: medium · scope of inference: Patients with L-DOPA or dopamine agonist-induced PD psychosis over 28 days.Key limitations: small sample · primary endpoint only a trend · efficacy significant on secondary measures only
Real-world observational support for the psychosis-improvement limb.
“Clinical improvement in psychosis was documented in 76% of patients (69/91)”
Panel auditInternal validity: low · scope of inference: Real-world patients with PD-related psychosis including dementia and prior antipsychotic failure, median follow-up 14.6 months.Key limitations: no control group · subjective charted outcomes · single centre
Previously-placebo patients improved on pimavanserin (SAPS-PD -3.4, p<0.0001) but this is an open-label within-subject change with no concurrent control, so the claim's contrast is not determinable.
Panel auditInternal validity: low · scope of inference: Patients completing the 6-week pivotal trial, over a further 4 weeks of open-label treatment.Key limitations: open-label, no concurrent control · short follow-up window · no motor outcome in abstract
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Both limbs are consistently supported and biologically coherent, but reliance on a single positive pivotal RCT for efficacy and short-term secondary motor assessments warrants a conservative upper-Likely tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmatory efficacy RCT. The efficacy limb rests chiefly on one pivotal RCT [1]; the only other RCT [2] met only secondary endpoints, so a second clearly positive primary endpoint is missing. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised, placebo-controlled trial by an independent group, powered on SAPS-PD as the primary endpoint.
Open question: Does an independent, adequately powered RCT replicate the SAPS-PD psychosis benefit seen in the pivotal trial [1]? Why it is still open: Only one RCT [1] was positive on its primary endpoint; the other [2] showed only a trend on SAPS total.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19